Novo Nordisk A/s

This study tests a new medicine called CagriSema (a mix of two drugs) for helping people with obesity lose weight. About 400 adults with a BMI of 35 or higher will receive either CagriSema or a placebo for 2 years, then some will continue or slowly stop the medicine for another y…

This study tests if a new growth hormone medicine (somapacitan) given once a week works as well as the standard daily growth hormone (Norditropin) for children who are very short due to being born small, or having Turner syndrome, Noonan syndrome, or unknown causes. About 412 chi…

This study follows 200 adults in Japan with severe growth hormone deficiency who are taking Sogroya as part of their normal care. Researchers will monitor side effects and changes in body composition over 2 to 5 years. Participants will also fill out quality-of-life questionnaire…

This study tests a new medicine (somapacitan) given once a week against a standard daily growth hormone (Norditropin) in children born small who remain short. About 62 children aged 2.5 to 11 years will receive either treatment for up to 5 years. The goal is to see if the weekly …

This study tests a new investigational medicine called CagriSema against an approved drug, tirzepatide, in people with type 2 diabetes whose blood sugar is not well controlled by current pills. About 1,023 adults will receive either CagriSema or tirzepatide once a week for up to …

This study looks at how well the drug Alhemo works and how safe it is for people with hemophilia A or B when used in normal medical care in Japan. About 23 participants will take Alhemo as their doctor prescribes and be followed for 2 years. The main goal is to count any side eff…

This study tests an experimental drug called cagrilintide to help people with overweight or obesity lose weight. About 300 adults will receive either the drug or a placebo for around 1.5 years. The main goal is to see how much weight they lose and if they achieve at least a 5% re…

This study tests whether a daily injection of liraglutide, already approved for adults, can help children aged 6 to 12 with obesity lose weight. About 78 children will receive either the drug or a placebo for 56 weeks, along with healthy eating and exercise advice. The main goal …

This study tests the long-term safety of an experimental medicine called NNC6019-0001 in people with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR CM). About 80 participants who completed a previous study will receive the medicine for up to 3 years. Res…

This study follows 600 adults with type 2 diabetes who are already starting Ozempic as part of their normal care. Researchers will track side effects and blood sugar control over about 26 weeks. The goal is to confirm the drug works safely in real-world settings, not just in cont…

This study tests a weekly injection of semaglutide (a medicine already used for weight loss in adults) in 210 children and teens aged 6 to 17 with obesity or overweight. Participants also receive counseling on diet and exercise. The goal is to see if the drug helps lower body mas…

This study tests an experimental medicine, cagrilintide, to see how well it helps people with overweight or obesity and type 2 diabetes lose weight. About 330 adults will receive either cagrilintide or a placebo for around 18 months. The main goals are to measure the percentage o…

This study tests a new growth hormone medicine called somapacitan, given once a week, in children who are short because they were born small for gestational age or have Turner syndrome, Noonan syndrome, or idiopathic short stature. About 47 children will receive the injection at …

This study will follow 500 Korean adults with obesity who are starting Wegovy (semaglutide) as part of their normal care. Researchers will track how much weight they lose and any side effects over about 52 weeks. The goal is to see how effective and safe the drug is in real-world…

This study will check how well insulin icodec controls blood sugar in 245 people with type 1 diabetes who have not used it before. Participants will take the insulin as their doctor prescribes, and the study lasts about 22 to 30 weeks. The main goal is to see changes in HbA1c, a …

This study tests if semaglutide, a drug already used for diabetes, can help people with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. About 1205 adults with liver scarring but not cirrhosis will receive weekly injections of either semaglutide or a placebo f…

This study is testing a new medicine called NNC0662-0419, given as a weekly injection, to see if it is safe and helps people with overweight or obesity lose weight. About 224 adults aged 18-65 with a BMI of 27 or higher will receive either the drug or a placebo. The main goals ar…

This study follows about 60 males with hemophilia A who are already using Esperoct to prevent bleeds. Researchers will track side effects and how well the medicine controls bleeding over 5-7 years. Participants continue their normal treatment and clinic visits, with no extra proc…

This study tests whether a weekly injection of semaglutide can help 500 adolescents with obesity lose weight and maintain that loss for at least 3 years. All participants receive the medicine, which is injected into the stomach, thigh, or upper arm. The goal is to see if the drug…

This study compares a new tablet form of semaglutide (oral semaglutide D) with the currently approved version in Japanese adults with type 2 diabetes. About 264 participants will be randomly assigned to one of the two treatments for 27 weeks. The main goal is to see if the new fo…

This early-stage study is testing a new drug called NNC0194-0499 in 96 adults with type 1 diabetes. The goal is to see if it can improve blood sugar levels when used alone or with another diabetes drug (semaglutide), while everyone continues their standard insulin therapy. The st…

This study tests the long-term safety and effectiveness of a new medicine called Mim8 in people with hemophilia A, including those with inhibitors. Mim8 helps replace the missing clotting factor to prevent bleeding episodes. About 451 participants will receive injections over up …

This study follows 200 children with growth hormone deficiency who are taking Sogroya, a growth hormone medication, to see how safe and effective it is over 1 to 3 years in everyday medical practice in Japan. Participants will answer a questionnaire about their treatment experien…

This study tests a daily injection called concizumab for people with hemophilia A or B who have inhibitors (antibodies that block standard treatment). The goal is to see if it safely prevents bleeding episodes. About 134 males aged 12 and older take part, with some starting the d…

This study tests whether a monthly injection of ziltivekimab can reduce the risk of heart attacks, strokes, and other cardiovascular events in 6,200 people who already have heart disease, chronic kidney disease, and signs of inflammation. Participants are randomly assigned to rec…

This study tests whether a weekly injection of CagriSema (a combination of two drugs) can reduce the risk of heart attacks, strokes, and other heart-related events in people with established cardiovascular disease. About 7,100 participants will receive either CagriSema or a place…

This study tests a medicine called concizumab for people with hemophilia A or B who do not have inhibitors. The goal is to see if a daily shot under the skin can prevent bleeding episodes safely. About 156 participants, aged 12 and older, will either start concizumab right away o…

This study follows over 1,000 people with obesity in Japan who are taking Wegovy as prescribed by their doctor. Researchers will track side effects and weight changes for about 2 years to see how the drug works in everyday life, not just in a lab. The goal is to better understand…

This study tests a daily injection called concizumab in children under 12 with hemophilia A or B, with or without inhibitors. The goal is to see if it safely prevents bleeding episodes. Participants receive daily shots under the skin for at least 2 years, and the study tracks how…

This study follows 1,250 people with obesity who are starting Wegovy as part of their regular medical care. Over two years, researchers will track changes in weight, waist size, and overall quality of life. The goal is to see how well the medication works in everyday situations, …

This study tests a once-weekly injection called CagriSema (a mix of two medicines) for weight loss and long-term weight maintenance in adults with obesity. About 600 participants will receive either CagriSema or a placebo for the first part, then all will receive CagriSema in an …

This study looks at whether semaglutide, a medicine for type 2 diabetes, affects diabetic eye disease over 5 years. About 1500 adults with type 2 diabetes will receive either semaglutide or a placebo injection once a week, in addition to their usual diabetes medicines. The main g…

This study tests a once-weekly injection called CagriSema, which combines two medicines (cagrilintide and semaglutide), to help people with obesity or overweight lose weight. About 3,400 adults will receive either CagriSema, one of the two medicines alone, or a placebo for 1.5 ye…

This study tests whether community programs that promote healthy eating and physical activity can prevent obesity in children aged 6-13 living in disadvantaged city areas. About 36,000 children from Australia, Brazil, Canada, Japan, South Africa, and Spain will take part. Researc…

This study tests a new medicine for people who are overweight or have obesity. The main goal is to check if the medicine is safe and how the body handles it. About 63 participants will receive either the study drug or a placebo as an injection under the skin. This is an early-sta…

This study tests a new medicine called CagriSema (a mix of two drugs) to see if it can reduce nerve pain in people with type 2 diabetes. About 142 adults will receive either the active drug or a placebo for around 10 months. The main goal is to measure changes in weekly pain scor…

This study monitors the long-term safety and effectiveness of the drug Alhemo in 30 people with hemophilia A or B who do not have inhibitors. Participants are treated in routine clinical practice in Japan and observed for about 2 years each. The goal is to track side effects and …

This study follows 60 males with hemophilia B who are already using the medication Refixia/REBINYN to prevent bleeding. Researchers will track side effects, bleeding episodes, and quality of life over 4 to 9 years. Participants continue their usual care and clinic visits, with no…

This study follows about 728 pregnant women who took Wegovy for weight loss and compares them to similar pregnant women who did not take the drug. Researchers will track birth defects and other health outcomes in babies up to one year old. The goal is to better understand the saf…

This study gathers safety information from a European registry for people with haemophilia A who are treated with turoctocog alfa pegol. Researchers will count any side effects reported to the registry that might be linked to the drug. About 50 participants are involved, and ther…

This study looks at health records of about 1,100 women who took Wegovy during pregnancy and compares them to those who did not. The goal is to see if the drug increases risks for birth defects or other problems in babies. Researchers will use insurance claims data to track outco…

This study looks at health records from 100,000 Chinese people with type 2 diabetes to compare heart and kidney outcomes between those taking Ozempic and those on other diabetes medications. Researchers will track major heart problems, strokes, and kidney events over time. No new…

This study looks at children and teenagers with growth hormone deficiency or who were born small for their age. It tracks how closely they follow their prescribed Norditropin® treatment and whether that affects their final height. The study is observational, meaning no new treatm…

This study collects information through online surveys from about 2,500 adults in Australia, Germany, UAE, and Spain who have been prescribed injectable semaglutide for weight management. The goal is to understand their characteristics, treatment experiences, and changes in weigh…

This study follows 500 children with growth hormone deficiency who are taking somapacitan (a once-weekly injection) as part of their normal medical care. Researchers will track side effects, medication errors, and new cases of cancer or type 2 diabetes over 10 years. The goal is …

This study is a registry that follows children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. It aims to collect long-term data on growth, safety, and quality of life. No new treatment is given; it simply observes real-world outcomes. Abou…

This study collects information from doctors and patient groups across Asia and the Pacific to better understand how haemophilia affects people in the region. No treatments or medications are given; instead, researchers will analyze data on how many people have the condition, how…

This study follows 400 adults with growth hormone deficiency who are already taking Sogroya as part of their normal care. Researchers will track side effects and effectiveness over 5 to 10 years. Participants will also complete short questionnaires about their well-being and dail…

This study follows 96 people with moderate Parkinson's disease for up to 24 months to see how their symptoms change. Participants take their usual medications, and doctors may adjust them for better control. The goal is to learn more about the disease's progression, not to test a…